# A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

> **NCT03162536** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 190 (estimated)

## Conditions studied

- Lymphoma, B-Cell
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Richter's Transformation
- Follicular Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Nemtabrutinib

## Key facts

- **NCT ID:** NCT03162536
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-26
- **Primary completion:** 2026-09-18
- **Final completion:** 2026-09-18
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162536, "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03162536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*